麗珠醫藥(01513.HK)與蘇州蘭晟醫藥簽署專利及技術轉讓協議
格隆匯10月12日丨麗珠醫藥(01513.HK)公吿,公司全資子公司麗珠集團麗珠製藥廠於2023年10月12日與蘇州蘭晟醫藥有限公司簽署了《專利及技術轉讓協議》。根據本協議,蘭晟同意將其研發的磷酸二酯酶4(PDE4)抑制劑(LS21031)在大中華區(中國大陸、香港特別行政區、澳門特別行政區及台灣地區)內的所有權利、所有權和權益轉讓並轉移給製藥廠。製藥廠需向蘭晟支付相應的專利及技術轉讓費(包括首付款、開發里程碑金及銷售里程碑金)及銷售提成。
LS21031是蘭晟自主研發的一款創新高選擇性磷酸二酯酶4D(PDE4D)變構調節劑,已於2023年3月在中國獲批臨牀,適應症為抑鬱症。現有資料表明,LS21031具有抗抑鬱起效速度快、安全性好等優勢,同時還有改善認知障礙的潛力。
目標產品在大中華區域內獲批上市銷售後,製藥廠應根據本協議向蘭晟支付大中華區域內全年淨銷售額不低於4%的銷售提成。銷售提成支付期限以目標產品上市銷售起10週年或直至目標產品化學結構的專利權到期日兩者較晚的期限屆滿為止。如果在大中華區域內某個區域出現第三方競品上市,則按本協議約定該區域減少銷售提成比例至1%。
本次技術引進可進一步豐富公司優勢領域的產品佈局,有利於提高公司的綜合實力,符合公司中長期創新發展的戰略佈局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.